Chronic stable coronary artery disease
Conditions
Interventions
Test group:CAD standard drug treatment with shexiangbaoxin pills, 2 pills each time, 3 times a day, for 2 years
Placebo group:CAD standard drug treatment with placebo, 2 pills each time, 3 times a day, for 2 years
Sponsors
Zhongshan Hospital Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 years at screening; 2. Patients who have ischemia myocardial symptoms and whose clinical symptoms keep stable for at least one month; 3. Have at least one of the following events (providing hospital records or inspection report): 1) history of acute myocardial infarction for at least half of a year; 2) history of PCI or CABG for at least half of a year; 3) coronary CTA angiography or coronary angiography shows that at least one of the main branchs of coronary artery stenosis is no less than 50%. 4. Provide informed consent form.
Exclusion criteria
Exclusion criteria: 1. History of acute myocardial infarction, vascular reconstruction, CABG or PCI within half of a year; 2. Prepared to undertake CABG or PCI during this study; 3. Serious cardiovascular diseases: sustained severe angina (CCS ?), refractory heart failure, cardiogenic shock, severe aortic stenosis or aortic insufficiency; 4. Severe respiratory diseases; 5. Diabetic patients with poor glycemic control (fasting blood glucose > 200 mg/dl or 11.1mmol/L for more than twice within one month before the study entry); 6. Hypertensive patients with poor control of blood pressure, SBP >=180mmHg or DBP>=110mmHg before entry; 7. Severe liver and kidney diseases,such as active liver disease, cirrhosis and uremia; 8. Any other severe diseases, such as malignant tumor, severe anemia and severe renal artery stenosis; 9. Unable or unwilling to sign informed consent form; 10. Join another trial or has received random allocation of this study within one month before entry; 11. Pregnant or who were attempting to become pregnant; 12. Patients who are regarded as not being suitable participants by the study investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiovascular death;Nonfatal myocardial infarction;Nonfatal strok; | — |
Secondary
| Measure | Time frame |
|---|---|
| All cause death;Coronary angioplasty;Due to unstable angina or heart failure hospitalization; | — |
Contacts
Public ContactGe Junbo
Outcome results
None listed